News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
739,080 Results
Type
Article (43741)
Company Profile (473)
Press Release (694854)
Multimedia
Podcasts (127)
Webinars (20)
Section
Business (209336)
Career Advice (2041)
Deals (36154)
Drug Delivery (120)
Drug Development (83982)
Employer Resources (174)
FDA (16702)
Job Trends (15191)
News (354209)
Policy (33292)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2661)
Accelerated approval (37)
Adcomms (28)
Allergies (150)
Alliances (51111)
ALS (181)
Alzheimer's disease (1740)
Antibody-drug conjugate (ADC) (337)
Approvals (16946)
Artificial intelligence (556)
Autoimmune disease (167)
Automation (43)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (197)
Biotechnology (331)
Bladder cancer (165)
Brain cancer (61)
Breast cancer (661)
Cancer (5020)
Cardiovascular disease (427)
Career advice (1726)
Career pathing (38)
CAR-T (296)
CDC (50)
Celiac Disease (2)
Cell therapy (792)
Cervical cancer (37)
Clinical research (71534)
Collaboration (1829)
Company closure (4)
Compensation (1202)
Complete response letters (67)
COVID-19 (2775)
CRISPR (102)
C-suite (910)
Cystic fibrosis (152)
Data (6431)
Decentralized trials (2)
Denatured (40)
Depression (146)
Diabetes (509)
Diagnostics (6776)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (275)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (251)
Earnings (91567)
Editorial (63)
Employer branding (21)
Employer resources (153)
Events (121245)
Executive appointments (1021)
FDA (19915)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1553)
Gene editing (219)
Generative AI (46)
Gene therapy (656)
GLP-1 (1014)
Government (4772)
Grass and pollen (6)
Guidances (385)
Healthcare (19217)
HIV (64)
Huntington's disease (47)
IgA nephropathy (88)
Immunology and inflammation (280)
Immuno-oncology (68)
Indications (122)
Infectious disease (3059)
Inflammatory bowel disease (206)
Inflation Reduction Act (17)
Influenza (122)
Intellectual property (260)
Interviews (316)
IPO (16933)
IRA (53)
Job creations (3714)
Job search strategy (1440)
JPM (66)
Kidney cancer (16)
Labor market (86)
Layoffs (582)
Leadership (34)
Legal (8030)
Liver cancer (93)
Longevity (15)
Lung cancer (680)
Lymphoma (388)
Machine learning (43)
Management (59)
Manufacturing (832)
MASH (173)
Medical device (13934)
Medtech (13992)
Mergers & acquisitions (20310)
Metabolic disorders (1335)
Multiple sclerosis (169)
NASH (19)
Neurodegenerative disease (349)
Neuropsychiatric disorders (98)
Neuroscience (3062)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4586)
Now hiring (68)
Obesity (640)
Opinion (287)
Ovarian cancer (169)
Pain (208)
Pancreatic cancer (239)
Parkinson's disease (301)
Partnered (34)
Patents (516)
Patient recruitment (514)
Peanut (59)
People (60393)
Pharmaceutical (85)
Pharmacy benefit managers (31)
Phase 1 (22498)
Phase 2 (31539)
Phase 3 (23313)
Pipeline (5587)
Policy (308)
Postmarket research (2602)
Preclinical (9615)
Press Release (67)
Prostate cancer (249)
Psychedelics (56)
Radiopharmaceuticals (304)
Rare diseases (919)
Real estate (6065)
Recruiting (71)
Regulatory (25110)
Reports (53)
Research institute (2491)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (21)
RSV (81)
Schizophrenia (158)
Series A (257)
Series B (203)
Service/supplier (11)
Sickle cell disease (106)
Special edition (27)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3806)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (85)
The Weekly (85)
Vaccines (1045)
Venture capital (96)
Weight loss (413)
Women's health (99)
Worklife (19)
Date
Today (147)
Last 7 days (714)
Last 30 days (2460)
Last 365 days (30791)
2026 (4295)
2025 (31066)
2024 (36299)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32348)
2015 (38397)
2014 (32185)
2013 (27110)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (754)
Alabama (91)
Alaska (7)
Arizona (321)
Arkansas (15)
Asia (40728)
Australia (6770)
California (11672)
Canada (3349)
China (1150)
Colorado (492)
Connecticut (505)
Delaware (344)
Europe (89358)
Florida (1732)
Georgia (367)
Hawaii (3)
Idaho (61)
Illinois (900)
India (71)
Indiana (535)
Iowa (24)
Japan (444)
Kansas (131)
Kentucky (42)
Louisiana (27)
Maine (72)
Maryland (1425)
Massachusetts (8477)
Michigan (331)
Minnesota (644)
Mississippi (5)
Missouri (131)
Montana (34)
Nebraska (28)
Nevada (124)
New Hampshire (84)
New Jersey (3104)
New Mexico (31)
New York (3051)
North Carolina (1556)
North Dakota (9)
Northern California (5693)
Ohio (343)
Oklahoma (21)
Oregon (45)
Pennsylvania (2336)
Puerto Rico (24)
Rhode Island (49)
South America (1122)
South Carolina (68)
South Dakota (1)
Southern California (4533)
Tennessee (178)
Texas (1788)
United States (41500)
Utah (348)
Vermont (1)
Virginia (273)
Washington D.C. (82)
Washington State (967)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
739,080 Results for "sarepta therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne muscular dystrophy pipeline, as Sarepta’s Elevidys leaves the door open.
February 9, 2026
·
11 min read
·
Heather McKenzie
Duchenne muscular dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.
January 26, 2026
·
2 min read
·
Dan Samorodnitsky
Duchenne muscular dystrophy
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up
After a series of deaths in patients taking Sarepta Therapeutics’ gene therapies, doubt has crept into investor sentiments around the long-time Wall Street darling, and patients may soon begin looking elsewhere.
February 5, 2026
·
5 min read
·
Dan Samorodnitsky
Gene therapy
After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026
Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.
January 13, 2026
·
2 min read
·
Tristan Manalac
Legal
REGENXBIO Secures Legal Win in Gene Therapy Patent Battle Vs. Sarepta
A lower court had previously ruled for Sarepta in the companies’ long-running dispute, finding that REGENXBIO’s AAV patent was invalid because its elements were naturally occurring. The appeals court on Friday said that this original decision adopts a “narrow” view of the invention.
February 23, 2026
·
2 min read
·
Tristan Manalac
Podcast
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as Health Secretary Robert F. Kennedy’s anti-vaccine policies and rhetoric continues; and embattled gene therapy maker Sarepta announces new data in Duchenne muscular dystrophy.
January 28, 2026
·
1 min read
·
Heather McKenzie
Press Releases
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
February 12, 2026
·
1 min read
Duchenne muscular dystrophy
Sarepta’s DMD Exon-Skippers Fail Confirmatory Study, Stock Craters
Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging trends” in efficacy.
November 4, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Imposes Boxed Warning, Narrows Patient Pool for Sarepta’s Duchenne Gene Therapy Elevidys
Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed with the gene therapy.
November 17, 2025
·
1 min read
·
Tristan Manalac
Gene therapy
Doctors Still Prescribing Sarepta’s DMD Gene Therapy After Safety Concerns
A new analyst survey suggests that doctors are still prescribing Sarepta’s Elevidys, even after a series of deaths in certain populations marred the gene therapy’s record.
September 16, 2025
·
3 min read
·
Annalee Armstrong
1 of 73,908
Next
